REMARKS

Amendment to Title:

The title has been changed to be that of the parent application, now US 6,825,344. Addition of Cross Reference:

The cross reference was added. Priority was claimed to the cited documents in the Application Data Sheet submitted with this pending application.

Amendments to Claim 1:

For clarity, the format of claim 1 was modified to have each variable begin on a separate line.

The term "CO₂R³" and related text was replaced by defining only R₃. Support for the definition is found on page 3, lines 12 and 19-20.

R⁴ was reworded to use "independently" rather than "which may be the same or different". The last sentence of claim 1 as originally filed on page 23, lines 17-18 was incorporated into the definition of R⁴ and deleted from the end of the claim. The wording was slightly changed by removing R⁴ within the phrase.

The terms "2-cephem" and "3-cephem" were replaced by referencing the double bond between either C2 and C3 or C3 and C4. See the attached common numbering of β -lactams from Avery's Drug Treatment, 4th Edition, page 1459.

Amendments to Claim 2:

The term "3-cephem" was replaced by reference to formula (II) with the double bond between C3 and C4 as discussed *infra*.

The definitions of the variables were added. Support is found at least on page 1, line 26 to page 2, line 7; and on page 3, lines 12 and 19-20.

Amendments to Claims 3-9, 12-13, 15-16:

The amendments are purely grammatical.

Amendments to Claim 10:

The "X" and "X1" in formula (V) were changed to "Y" and "Y1", respectively.

Definitions for the variables were added. Support is found at least on page 1, line 26 to page 2, line 7; and on page 3, lines 12 and 19-20. Support specifically for R² is on page 10, lines 5-6.

Other amendments are purely grammatical.

Amendments to Claim 11:

Definitions for the variables were added. Support is found at least on page 1, line 26 to page 2, line 7; and on page 3, lines 12 and 19-20. Support specifically for R² is on page 10, lines 5-6.

Support for the text regarding formula VIII then being hydroxylated to form a compound of formula III is found on page 12, lines 4-5. Support for reference to a compound of formula (IV) is found on page 12, lines 9-10.

Other amendments are purely grammatical.

Amendments to Claim 14:

Definitions for the variables were added. Support is found at least on page 1, line 26 to page 2, line 7.

The variable Y in the definition of Z was changed to Z' so the same letter was used throughout that claim.

Other amendments are purely grammatical.

Amendments to Claim 17:

The phrase "a pinacol boronate group or" was removed from claim 17.

Other amendments are purely grammatical.

Amendments to Claim 18:

The definitions of the variables were added. Support is found at least on page 1, line 26 to page 2, line 7; and on page 3, lines 12 and 19-20.

Reference to "cephem" was removed and reference to the compound formula was used.

Word order was changed slightly and other grammatical changes made.

New Claim 22:

Support for this claim appears on at least page 3, lines 12-10.

New Claim 23:

Support for this claim appears on at least page 5, lines 10-20.

The amendments do not add new subject matter.

IDS

A copy of the 1449 from the parent case are provided herewith. The references can be found in the file of the parent case. A copy of the signed 1449 for one of the 1449 forms submitted is provided herewith because of hand writing on it regarding the citation, with the hand writing apparently being from the Examiner.

Conclusion

Applicants believe that the claims are in order for allowance, early notice of which is requested. If Examiner has any questions concerning this application, Examiner is invited to contact the below-signed attorney.

Date: 14 December 2004

Respectfully submitted,

Registration No. 48,324

Pfizer, Inc Global Intellectual Property 301 Henrietta Street Kalamazoo, Michigan 49001 Telephone No. (269) 833-0975 or (269) 833-9500 Telefax No. (269) 833-8897 or (269) 833-2316